The PE Ratio as of November 2024 (TTM) for Finch Therapeutics Group, Inc. (FNCH) is -1.36

According to Finch Therapeutics Group, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.36. This represents a change of 217.56% compared to the average of -0.43 of the last 4 quarters.

Finch Therapeutics Group, Inc. (FNCH) Historical PE Ratio (quarterly & annually)

How has FNCH PE Ratio performed in the past?

The mean historical PE Ratio of Finch Therapeutics Group, Inc. over the last ten years is -17.08. The current -1.36 PE Ratio has changed 696.14% with respect to the historical average. Over the past ten years (40 quarters), FNCH's PE Ratio was at its highest in in the March 2023 quarter at -0.07. The PE Ratio was at its lowest in in the September 2021 quarter at -15.49.

Finch Therapeutics Group, Inc. (FNCH) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Finch Therapeutics Group, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Finch Therapeutics Group, Inc. (FNCH) Average PE Ratio

How has FNCH PE Ratio performed in the past?

The current PE Ratio of Finch Therapeutics Group, Inc. (FNCH) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Finch Therapeutics Group, Inc. (FNCH) PE Ratio vs. Peers

How is FNCH’s PE Ratio compared to its peers?

Finch Therapeutics Group, Inc.’s PE Ratio is greater than Werewolf Therapeutics, Inc. (-1.83), greater than Edgewise Therapeutics, Inc. (-27.83), greater than Decibel Therapeutics, Inc. (-1.94), greater than Celcuity Inc. (-7.15), greater than C4 Therapeutics, Inc. (-4.26), less than Ikena Oncology, Inc. (-1.24), greater than Design Therapeutics, Inc. (-5.95), less than Xilio Therapeutics, Inc. (-1.27), greater than Eliem Therapeutics, Inc. (-2.42), greater than Monte Rosa Therapeutics, Inc. (-4.83), greater than Stoke Therapeutics, Inc. (-7.05), less than Virax Biolabs Group Limited (-0.68), less than Blue Water Vaccines, Inc. (-0.17), less than Revelation Biosciences, Inc. (-0.09), less than Hillstream BioPharma, Inc. (-0.00), less than Kiora Pharmaceuticals, Inc. (4.79), greater than Nutriband Inc. (-8.87), less than Quoin Pharmaceuticals, Ltd. (-0.44), less than Longeveron Inc. (-0.72), greater than RenovoRx, Inc. (-3.08),

Build a custom stock screener for Finch Therapeutics Group, Inc. (FNCH) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Finch Therapeutics Group, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Finch Therapeutics Group, Inc. (FNCH) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Finch Therapeutics Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.